To date a number of private and public sector initiatives have commenced that rely on value-driven principles for the delivery of health care services. Given the variation that may exist across these initiatives it is important to have a good structure for examining and evaluating their implementation and overall effectiveness.
Prescription Drugs & Other Medical Products
Drugs and other medical products greatly impact human health and the health care system. ASPE conducts a variety of research in this area, including work related to medical product development and regulation; medical product markets, pricing and competition; prescription drug benefits and spending on medical products; medical product supply chains; and medical product safety.
Noteworthy
Reports
Displaying 131 - 140 of 173. 10 per page. Page 14.
Advanced SearchA Framework for Evaluating Price Transparency Initiatives in Health Care
To date a number of private and public sector initiatives have commenced that rely on value-driven principles for the delivery of health care services. Given the variation that may exist across these initiatives it is important to have a good structure for examining and evaluating their implementation and overall effectiveness.
Prescription Drug Spending by Medicare Beneficiaries in Institutional and Residential Settings, 1998-2001
U.S. Department of Health and Human Services
Drug Use and Spending for Medicare Beneficiaries During Part A Qualifying Skilled Nursing Facility Stays and Non-Qualifying Long-Term Care Facility Stays
This Policy Brief helps fill an important gap in our understanding of medication patterns in long-term care facilities (LTCFs) by comparing use and spending for prescription and over-the-counter drugs during skilled nursing facility (SNF) stays and related non-qualifying long-term care facility episodes.
A National Comparison of Prescription Drug Expenditures by Medicare Beneficiaries Living in the Community and Long-Term Care Facility Settings
This Policy Brief provides a snapshot of prescription drug use and spending in 2001, the latest year for which complete community and long-term care facility drug data are available.
Analysis of Supply, Distribution, Demand, and Access Issues Associated with Immune Globulin Intravenous (IGIV)
Contents IGIV Supply and Distribution - Key Findings IGIV Demand - Key Fundings IGIV Access Problems- Key Fundings Immune globulin intravenous (IGIV), also referred to as intravenous immune globulin (IVIG), is a valuable treatment for many seriously ill patients. Although the U.S.
Report
An Overview of the US Health System Chart Book
Report authors : George Greenberg, Nancy DeLew Office of the Assistant Secretary for Planning and Evaluation (ASPE) U.S. Department of Health and Human Services
Cost Effectiveness Considerations in the Approval and Adoption of New Health Technologies
Contents Background and Purpose Methodology Summary of Key Findings and Stakeholder Suggestions Conclusions and Policy Implications A.
Continuation of Drug Risk Adjustment
Prepared by: National Opinion Research Center (NORC) at the University of Chicago Prepared for:U.S. Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation
Compendium of Home Modification and Assistive Technology Policy and Practice Across States: Final Report
U.S. Department of Health and Human Services